Core Viewpoint - Moderna has experienced a significant increase in stock value, gaining over 12% recently, driven by positive developments in its vaccine research [1]. Group 1: Vaccine Development - Moderna published results from a late-stage study of its seasonal flu vaccine, mRNA-1010, which demonstrated a stronger immune response compared to standard flu vaccines [2]. - The company plans to resubmit its application for a combination COVID-19/flu vaccine, following the withdrawal of its previous application in May [4]. - CEO Stéphane Bancel highlighted the trial results as a significant milestone in reducing influenza burden in older adults [5]. Group 2: Market Sentiment - Despite the positive news regarding the flu vaccine, there is skepticism about whether this development alone will make Moderna's stock a compelling buy [5]. - The company has a robust pipeline of development programs, which could enhance the attractiveness of its shares if any show promise [6].

新华社北京7月4日电（记者阳娜）数字技术快速发展的浪潮下，未来生活将发生怎样的变化？正在举行 的2025全球数字经济大会上，"数字潮市"北京坊数字综合体正式亮相，增强现实（AR）、混合现实 （MR）、生成式人工智能（AIGC）等前沿技术深入生活的应用场景在此展出，带着大家一起解锁未来 生活的无限想象空间。 想象一下这样的场景：在摄像机前拍张照片，就能将你一键变成故事里的主人公，文案瞬间生成；口述 一个故事，不到一分钟就自动生成一个绘本，把你的"天马行空"变成精彩的画面；在屏幕前指定的空间 区域内挥动手臂"指指点点"，就能快速完成一幅精美的绘画作品，让你秒变"画家"…… 多项核心技术创新成果在此汇聚——一个手掌大小的终端设备"数字精灵导览器"，融合AI语音交互与高 透光3D成像技术，游客手持设备即可触发景点、展品的3D全息解说；混合现实研学空间"未来场域探索 馆"通过LBE大空间定位技术与实物教具联动，构建"航空航天主题MR课堂"…… 北京广安控股集团有限公司北京坊数字综合体运营负责人王臣说："这几天每天人流量基本能达到2500 至2800人左右，XR沉浸式展览院线、C919模拟驾驶舱等项目前常排起长队。" 图 ...

深圳市联得自动化装备股份有限公司 投资者关系活动记录表 A2：公司柔性 AMOLED 贴合类设备已经广泛运用国内外知名终端客 户手机折叠屏的量产。公司与国内外多家智能手机知名品牌制造商保持良 好的合作关系，并持续就柔性屏创新性作用开展深入合作。在三折屏供应 链中，公司提供的贴合类工艺设备已形成销售订单并出货。公司作为折叠 屏贴合类设备相关细分市场的领先企业，持续发挥技术领先优势。 Q3：公司在固态电池业务方面有哪些技术储备和进展？ 深圳市联得自动化装备股份有限公司 A3：在新能源设备领域，公司持续增加在锂电池包蓝膜、切叠一体机、 电芯装配、超声波焊接及 Pack 段整线自动化设备等设备上的研发投入，运 用先进的生产工艺、高精度的生产方式、标准化的管理，迅速实现产品突 破，并形成销售订单。固态电池新工艺涉及到的超声波焊接工艺设备已经 出货到客户。 投资者关系活动记录表 | 证券简称：联得装备 | 证券代码：300545 编号：2025-009 | | --- | --- | | 投资者关系活动类别 | █特定对象调研 □分析师会议 | | | □媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | ...

Pipeline and Clinical Trials - Cartesian Therapeutics is pioneering mRNA cell therapies for autoimmunity, with multiple anticipated near-term catalysts[5] - Phase 3 AURORA study of Descartes-08 for Myasthenia Gravis (MG) is expected to commence in 1H25[8] - An open-label Phase 2 trial of Descartes-08 in Systemic Lupus Erythematosus (SLE) is ongoing, with data readout expected in 2H25[8] - A Phase 2 pediatric basket trial, including juvenile SLE, juvenile MG, and other conditions, is expected to initiate in 2H25[8, 12] - Dosing is underway in a first-in-human Phase 1 dose escalation trial for Descartes-15, a next-generation mRNA CAR-T candidate[8] Descartes-08 Efficacy and Safety - In a Phase 2b trial, participants treated with Descartes-08 maintained deep and durable responses over 12 months[16] - At Month 4, participants in the primary efficacy dataset experienced an average MG-ADL reduction of 5.5 points[23] - 33% of participants achieved minimum symptom expression at Month 6[23] - 80% of participants reaching Month 12 maintained a clinically meaningful response[23] - In participants with no prior exposure to biologics, the average MG-ADL reduction was 6.6 points at Month 4[26] - 57% of participants with no prior exposure to biologics achieved minimum symptom expression at Month 6[26] - 100% of participants with no prior exposure to biologics reaching Month 12 maintained a clinically meaningful response[26] - The safety profile of Descartes-08 supports outpatient administration, with no new types of adverse events reported[16, 28] Financial Position - Cartesian Therapeutics has a strong balance sheet with approximately $220.9 million as of September 30, 2024[9] - This is expected to support planned operations, including completion of the planned Phase 3 trial of Descartes-08 for MG, into mid-2027[9]

新华财经上海7月4日电（谷青竹）早在1961年就被发现的mRNA（信使核糖核酸），疫情期间曾发挥重 要作用。当应急红利已成历史注脚，这项技术如何在更广泛的治疗领域里找到用武之地？ 近期，在港股上市的创新药企云顶新耀举办"mRNA创新技术平台研发日"。透过其展示的AI+mRNA技 术自主平台，以及基于该平台开发的肿瘤及自身免疫疾病领域核心管线的最新进展，公众得以窥见这一 命题的潜在答案。 重估mRNA平台价值 红红火火的mRNA新冠疫苗管线，近年来逐渐走向降温。 以行业巨头为例：2020年疫情期间，因mRNA疫苗具有研发周期短、免疫原性强等优势，英国政府批准 使用辉瑞（Pfizer）和拜恩泰科（BioNTech）合作生产的新冠疫苗，同年底莫德纳（Moderna）旗下的 mRNA新冠疫苗也获得美国FDA的紧急使用授权。到2021年，莫德纳实现营收184.71亿美元、净利润 122.02亿美元，拜恩泰科实现营收189.8亿欧元，双双跻身全球药企TOP50行列。 随着疫情结束，2023年莫德纳全年营收68亿美元，到2024年更是腰斩至32亿美元。拜恩泰科的情况同样 不乐观，在2024年出现了约7亿欧元的净亏损。 不过 ...

Core Viewpoint - Ningbo Meihua Pharmaceutical Co., Ltd. (Meihua) expects significant profit growth for the first half of 2025, driven by increased revenue and improved gross margins [1][2]. Financial Performance - The projected net profit attributable to shareholders is between 46 million to 52 million yuan, representing a year-on-year increase of 142.84% to 174.52% [1]. - The net profit after deducting non-recurring gains and losses is expected to be between 30.6252 million to 36.6252 million yuan, reflecting a year-on-year increase of 55.80% to 86.33% [1]. Business Growth Drivers - The growth in Meihua's performance is attributed to rising pharmaceutical demand, optimized cost control, and increased R&D investment [2]. - The company’s product offerings align with market demands driven by an aging population, enhancing profitability and core competitiveness [2]. International Expansion - Meihua's overseas business has been growing rapidly, with foreign revenue accounting for 69.77% of total revenue in 2024, predominantly from the European market [2]. - The company has established long-term partnerships with renowned pharmaceutical firms such as KRKA, MSD, and SERVIER, showcasing a competitive advantage through an integrated model of formulations and active pharmaceutical ingredients [2]. Innovation and R&D - Meihua is advancing its internationalization efforts while increasing its focus on innovative R&D, including a strategic collaboration with the University of Michigan for the development of the GLP-1 delivery system product "JH389" [3]. - Positive data from animal models have been reported, with plans for commercialization in Europe expected to commence after regulatory approval in 2026 [3]. Diverse Growth Strategies - The company is pursuing multiple business lines, including formulations, CDMO, and innovative projects, which collectively support diversified growth [4]. - Meihua's dual strategy of leveraging both international and domestic markets positions it well to capitalize on global opportunities while ensuring steady development through local resources [4].

上市公司如何平衡好经营的可持续性与未来性？ 日前，在云顶新耀医药科技有限公司(以下简称"云顶新耀")的mRNA(信使核糖核酸)创新技术平台研发 日上，云顶新耀首席执行官罗永庆对《证券日报》记者表示，通过"授权引进+自主研发"的双轮驱动战 略，云顶新耀逐渐实现了这一平衡。 具体来看，在经营层面，云顶新耀以引进的大单品实现了较为稳定的现金流；在布局创新上，公司通过 聚焦mRNA疗法等前沿技术，陆续产出了一些成果。罗永庆表示，基于mRNA创新技术平台，云顶新耀 已开发了通用型现货肿瘤治疗性疫苗EVM14、个性化肿瘤治疗性疫苗EVM16、自体生成CAR-T(嵌合抗 原受体T细胞免疫疗法)三款核心产品管线。"公司已与全球排名前20的药企广泛接洽，未来将通过与国 际伙伴合作，推动这些创新成果走向全球市场。" 夯实竞争优势 彻底治愈肿瘤是许多生命科学家的梦想。然而，现有的治疗技术难以在人体内建立起持久的免疫记忆， 因此对降低肿瘤复发率的作用有限。通过改造mRNA，却有可能取得突破。 "mRNA疗法借由基因编辑技术，改造细胞内负责传递遗传指令的mRNA，进而让细胞生产出特定的蛋 白质，可用于治疗肿瘤、传染病、自身免疫性疾病等 ...

Oncology Pipeline & Strategy - BioNTech has a multiplatform oncology portfolio with over 20 ongoing Phase 2 or 3 trials[7] - BNT327, a PD-L1/VEGF-A antibody, is a priority program with potential as a next-generation IO-backbone, with clinical activity observed across multiple indications in over 750 patients enrolled in 20+ clinical trials[7, 19, 20] - BNT327 combined with chemo in 1L TNBC showed an objective response rate (ORR) of 769% in PD-L1 negative, 563% in PD-L1 low, and 100% in PD-L1 high patients[25] - FixVac and iNeST are novel mRNA cancer immunotherapies targeting tumor-associated antigens and cancer mutations[7, 37] COVID-19 Vaccine & Financials - BioNTech anticipates maintaining a high market share in the U S, EU, and Japan for its COVID-19 vaccine[49] - The company expects total revenues between €1700 million and €2200 million for the financial year 2025[51] - R&D expenses for FY 2025 are projected to be between €2600 million and €2800 million[51] - SG&A expenses are estimated to be between €650 million and €750 million, with capital expenditure for operating activities between €250 million and €350 million[51] Financial Position - As of December 31, 2024, BioNTech's total cash plus security investments amounted to €174 billion, including €97619 million in cash and cash equivalents, €65362 million in current security investments, and €10611 million in non-current security investments[7, 8]

mRNA技术的突出优势在于将药物开发从"分子筛选"转变为"信息设计"，将人体自身变成了一个生产蛋 白药物的智能工厂。此外，mRNA技术集合了软件式平台、通用型生产平台的优势，具备覆盖从肿瘤到 自免、代谢性疾病、传染病、罕见病等多种难治性疾病的药物开发能力。 来源：环球网 【环球网报道 记者 姚倩】BioNTech今年年初在《Nature》发表了题为：RNA neoantigen vaccines prime long-lived CD8+T cells in pancreatic cancer的文章，引发了学术界和制药界的关注，该研究展示了mRNA 新抗原疫苗在胰腺癌治疗中的潜力，通过诱导长效、功能性的T细胞反应，有望为癌症免疫治疗带来新 希望。 肿瘤的复发和转移仍是临床治疗非常大的难题。在肿瘤免疫治疗中，mRNA技术如何发挥作用，国内生 物医药企业的自研mRNA平台又取得了哪些突破性的进展？近日，云顶新耀首席执行官罗永庆接受了环 球网记者的采访。 mRNA肿瘤疫苗预防肿瘤复发后转移的原理是什么？据罗永庆介绍，mRNA技术通过特定编码的mRNA 序列，进入到细胞后，会通过抗原递送细胞捕获、刺激T细胞和B细胞， ...

交银国际研究 每日晨报 2025 年 7 月 3 日 今日焦点 | 北方华创 | | 002371 CH | | --- | --- | --- | | 国产半导体设备龙头：成长性与韧性兼备，首 | | 评级: 买入 | | 予买入 | | | | 收盘价: 人民币 443.30 | 目标价: 人民币 530.00 | 潜在涨幅: +19.6% | | 王大卫, PhD, CFA | Dawei.wang@bocomgroup.com | | 半导体行业国产替代最核心的环节：正如之前主题报告中所提到的，我 们看好国产半导体设备行业前景，并关注龙头公司北方华创。 下游需求持续旺盛，国产设备市占率提升：中国内地半导体设备市场在 全球市场的份额从 2015 年的 13%升至 2024 年的 42%。在这个过程中， 北方华创业绩在上行周期中表现出高成长性，在下行周期中韧性较强。 与市场一致预测同比下降不同，我们预测中国内地 2025 年市场将保持增 长，达 500 亿美元。进口设备占比呈下降趋势，我们估算从 2015 年的 91.8%到 2024 年的 67.6%。我们预测北方华创 2025 年在内地半导体设备 市场 ...